PLSE · Pulse Biosciences, Inc · Stock research

Current Thesis

Pulse Biosciences is a pure-play bet on nanosecond pulsed-field ablation (nsPFA / nPulse), a non-thermal bioelectric platform aimed at cardiac atrial fibrillation and image-guided thyroid procedures. The leg that repriced this stock — sell-side discovery — has now fully played out. In roughly five weeks it went from a single Canaccord initiation (Buy, $32, 2026-06-04) to a three-broker Strong Buy cluster averaging $30.67, plus S&P Healthcare Equipment Select Industry Index inclusion on 2026-06-12. Price followed: a 52-week high of $31.00 in mid-June, then a month of chop between roughly $25.87 and $28.68, closing 2026-07-17 at $28.68 (+4.75% on the session). That leaves about 7% to the consensus target and about 8% to the Canaccord high. The warrant overhang closed cleanly on 2026-07-13. What is missing is a reason for the next 20%: the pivotal AFib endpoints read in 2027, commercial launch is guided to 2028, and the only dated event inside 30 days is an August 11 print with $0.4M of quarterly product revenue behind it. The narrative is intact and the theme has matured — this is now a range at full valuation rather than a breakout with room.

Bullish and bearish views on Pulse Biosciences, Inc

The model's bull view on Pulse Biosciences, Inc (PLSE), in brief: Discovery cluster is complete and consistent. The bear view: Price is inside the targets. $28.68 against a $30.67 average and a $32 high. The repricing that the coverage cluster was supposed to deliver has been delivered. Buying here is paying consensus for a 2028 launch. Nothing de-risks the story for 12+ months. Enrollment completes… Both cases follow in full.

Bull Case

• Discovery cluster is complete and consistent. Canaccord Buy $32 (2026-06-04, William Plovanic), Mizuho Buy $30 (Anthony Petrone), Oppenheimer Buy $30 (Suraj Kalia). Three-for-three Buy, average $30.67, no dissent. Coverage initiations on a pre-revenue medtech usually cluster in threes and then go quiet until data.
• Dilution overhang is mechanically gone. The final 200% warrants ($11.00 strike, deep in the money) expired 2026-07-13; Cumulative warrant proceeds reached $63.7M on top of the $60M July 2024 rights offering, with roughly $2.1M in the final tranche.
• Pivotal trial is running ahead of its own guide. NANOPULSE-AF dosed its first seven patients 2026-04-07 at St. Bernards Medical Center (Devi Nair, PI); ~215 patients across up to 30 US and European sites, Bayesian 6/12-month primary endpoints. Management pulled enrollment-completion guidance forward to early-Q4 2026 citing investigator enthusiasm.
• Feasibility data is genuinely strong. 100% acute procedural success, 96% at 12 months, 90% Kaplan-Meier freedom from arrhythmia at 12 months, against a 20–25% typical AF recurrence benchmark. European one-year outcomes were a Heart Rhythm 2026 late-breaker (2026-04-25, Vivek Reddy).
• Thyroid is a real second shot, not filler. The PRECISE benign-nodule study finished its first 50 patients and expanded toward 100; first-in-human data showed 74% volume reduction at 15–22 months with no regrowth and no serious adverse events. Vybrance PTM feasibility has enrolled at Sarasota Memorial and MD Anderson.
• Robert Duggan — who sold Pharmacyclics to AbbVie for $21B
• Hiring signals commercial intent. Inducement grants to three new employees were approved 2026-07-13 and disclosed 2026-07-15 under Nasdaq Rule 5635(c)(4).

Bear Case

• Price is inside the targets. $28.68 against a $30.67 average and a $32 high. The repricing that the coverage cluster was supposed to deliver has been delivered. Buying here is paying consensus for a 2028 launch.
• Nothing de-risks the story for 12+ months. Enrollment completes early-Q4 2026; the 6- and 12-month endpoints land through 2027. Between now and then the tape is headline-dependent with no scheduled data.
• A $1.98B market cap sits on $751k of trailing revenue. Q1 2026 posted a $18.6M GAAP net loss on $0.4M of product revenue, with $14.6M of operating cash burn. Cash fell to $68.3M from $80.7M at 2025-12-31. Sell-side models roughly $42.3M of revenue by 2029, which means the current cap discounts a successful PMA, a clean launch, and share gains against Boston Scientific's Farapulse and Medtronic's PulseSelect — incumbents already commercial in PFA.
• Another raise is arithmetic, not opinion. ~$60M of ATM capacity and a $200M shelf remain against a ~$74.7M annual loss run-rate. Insider ATM buying softens the optics but still issues shares.
• 71.6% ownership is a two-sided risk. Low effective float amplifies moves up and makes any Duggan ownership-reduction filing a violent, immediate de-rate with no natural bid underneath.
• Index inclusion is a spent catalyst. The ~5% pop on 2026-06-12 was the passive bid arriving. It does not repeat.

Setup & Price Structure

The June leg was clean: base near $24 through late May, breakout on the Canaccord initiation, extension into $31.00 by mid-June. Since then the stock has traded a $25.87–$30.13 range for roughly a month — a sideways digestion of the discovery move, with the 2026-07-17 close at $28.68 sitting in the upper half of that range after a +4.75% session. Structure is constructive, not broken. What it is not is a fresh breakout: the mid-June high has not been reclaimed, volume has thinned (328,240 shares on 2026-07-17), and the range top coincides with where every published target sits. Beta of 1.65 means the name will amplify any healthcare or small-cap risk-off move. The tradeable structure is a range: strength into $31.00 without new data is supply, and the $24 shelf is where the entire June thesis was built. A close through $31.00 on a dated catalyst would restart the trend; absent that, the setup is a pass for fresh capital.

Catalyst Calendar (next 30 days)

• 2026-08-11 — Q2 2026 earnings and business update (some vendors list 08-12). Consensus -$0.29 EPS. The line that matters is not revenue, it is cash: Q1 exited at $68.3M with $14.6M of quarterly operating burn. A cash figure implying a 2026 raise rather than 2027 changes the dilution timeline. Second item: reaffirmation of the early-Q4 2026 NANOPULSE-AF enrollment-completion guide.
• ~2026-07-20 to 2026-08-10 — no scheduled clinical or regulatory events. The window between now and the print is headline-driven only: possible additional site activations, a fourth broker initiation, or thyroid enrollment updates.
• Beyond the window (dated, for positioning): early-Q4 2026 NANOPULSE-AF enrollment completion; year-end 2026 Vybrance PTM enrollment completion; end-H1 2027 NANOCLAMP-AF surgical enrollment; 2027 AF primary endpoints; 2028 guided commercial launch.

Elapsed catalysts

• Elapsed and closed: 2026-07-13 warrant redemption deadline. The final 200% warrants have expired; this is no longer a forward catalyst. (passed 27d ago)

What Would Change Our Mind

• Upside re-rate: a fourth initiation with a target above $32, or an early NANOPULSE-AF enrollment-completion announcement pulled into Q3 2026, would restart the discovery leg and justify paying above the current range. A reclaim and hold of $31.00 on that news is the trigger to treat this as a trend again rather than a range.
• Thesis break: a weekly close below $24 loses the early-June base where coverage was initiated and would mean the market has repriced the discovery narrative entirely. Secondary conditions that break the story independent of price: enrollment slipping past the early-Q4 2026 guide, a Duggan ownership-reduction filing, or a Q2 cash disclosure that forces a raise into 2026 instead of 2027.
• Neutral outcome that still argues for standing aside: the August 11 print passes with reaffirmed guidance and no new data, leaving the stock ranging $26–$31 with dead time premium into 2027. That is the base case and it is not worth the opportunity cost of the capital.

Correlation Notes

• PFA complex: trades on the same narrative as Boston Scientific (BSX, Farapulse) and Medtronic (MDT, PulseSelect), but inversely on competitive news — a strong Farapulse quarter is a headwind for the nsPFA differentiation story, not a tailwind. Peer confirmation does not work in this cluster the way it does in a theme trade.
• Pre-revenue medtech / SMID biotech beta: correlates with XBI and small-cap healthcare risk appetite far more than with the medtech-equipment index it was added to on 2026-06-12. Beta 1.65 against a $1.98B cap with 71.6% locked up means the float is thin enough that broad risk-off moves overshoot.
• Rates sensitivity: a 2028 launch and 2029 revenue ramp make this a long-duration cash-flow asset. It behaves like a growth-duration proxy — moves inverse to the long end more than the underlying clinical progress justifies.
• Single-holder correlation: because Duggan controls 71.6%, the effective correlation to any other name is lower than the beta implies on the way up, and the idiosyncratic risk of a single Form 4 dominates every macro factor listed above.